Comparison in Short-Term Safety and Efficacy between New-Generation WATCHMAN FLX and Conventional WATCHMAN 2.5 for Percutaneous Left Atrial Appendage Closure
Background: Percutaneous left atrial appendage closure using the WATCHMAN system, to prevent thrombosis and minimize anti-coagulant use in patients with non-valvular atrial fibrillation, has recently been introduced. The safety and efficacy of new-generation WATCHMAN FLX, as compared to conventional...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/6/1618 |
| _version_ | 1797470571308515328 |
|---|---|
| author | Nobuyuki Fukuda Teruhiko Imamura Shuhei Tanaka Naoya Kataoka Ryuichi Ushijima Hiroshi Ueno Koichiro Kinugawa |
| author_facet | Nobuyuki Fukuda Teruhiko Imamura Shuhei Tanaka Naoya Kataoka Ryuichi Ushijima Hiroshi Ueno Koichiro Kinugawa |
| author_sort | Nobuyuki Fukuda |
| collection | DOAJ |
| description | Background: Percutaneous left atrial appendage closure using the WATCHMAN system, to prevent thrombosis and minimize anti-coagulant use in patients with non-valvular atrial fibrillation, has recently been introduced. The safety and efficacy of new-generation WATCHMAN FLX, as compared to conventional WATCHMAN 2.5, remain unknown. Methods: Consecutive patients who received percutaneous left atrial appendage closure using the WATCHMAN system in our institute, between June 2020 and December 2021, were retrospectively analyzed. Safety and efficacy during the 45-day observational period were compared between the two devices. Results: A total of 93 patients (73.0 ± 7.3 years old, 63 men) who received WATCHMAN FLX (<i>n</i> = 44) or WATCHMAN 2.5 (<i>n</i> = 49) were included. The device implant success rate was 100% in the FLX device group and 98% in the 2.5 device group. There were no procedure-related complications in the FLX group, and one non-relevant pericardial effusion in the 2.5 device group. During the 45-day observational period, there were no procedure-related adverse events. No patients in the FLX group had a peri-device leak >3 mm, whereas two patients in the 2.5 device group had a peri-device leak >3 mm. Anti-coagulants could be terminated in most of the patients (85% versus 88%; <i>p</i> = 0.68). Conclusions: Percutaneous left atrial appendage closure using new-generation WATCHMAN FLX seemed to be as safe and effective as conventional WATCHMAN 2.5 during the short-term observational period. |
| first_indexed | 2024-03-09T19:38:03Z |
| format | Article |
| id | doaj.art-f567334b292d41698694f8705e3e5311 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T19:38:03Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-f567334b292d41698694f8705e3e53112023-11-24T01:49:27ZengMDPI AGJournal of Clinical Medicine2077-03832022-03-01116161810.3390/jcm11061618Comparison in Short-Term Safety and Efficacy between New-Generation WATCHMAN FLX and Conventional WATCHMAN 2.5 for Percutaneous Left Atrial Appendage ClosureNobuyuki Fukuda0Teruhiko Imamura1Shuhei Tanaka2Naoya Kataoka3Ryuichi Ushijima4Hiroshi Ueno5Koichiro Kinugawa6The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanBackground: Percutaneous left atrial appendage closure using the WATCHMAN system, to prevent thrombosis and minimize anti-coagulant use in patients with non-valvular atrial fibrillation, has recently been introduced. The safety and efficacy of new-generation WATCHMAN FLX, as compared to conventional WATCHMAN 2.5, remain unknown. Methods: Consecutive patients who received percutaneous left atrial appendage closure using the WATCHMAN system in our institute, between June 2020 and December 2021, were retrospectively analyzed. Safety and efficacy during the 45-day observational period were compared between the two devices. Results: A total of 93 patients (73.0 ± 7.3 years old, 63 men) who received WATCHMAN FLX (<i>n</i> = 44) or WATCHMAN 2.5 (<i>n</i> = 49) were included. The device implant success rate was 100% in the FLX device group and 98% in the 2.5 device group. There were no procedure-related complications in the FLX group, and one non-relevant pericardial effusion in the 2.5 device group. During the 45-day observational period, there were no procedure-related adverse events. No patients in the FLX group had a peri-device leak >3 mm, whereas two patients in the 2.5 device group had a peri-device leak >3 mm. Anti-coagulants could be terminated in most of the patients (85% versus 88%; <i>p</i> = 0.68). Conclusions: Percutaneous left atrial appendage closure using new-generation WATCHMAN FLX seemed to be as safe and effective as conventional WATCHMAN 2.5 during the short-term observational period.https://www.mdpi.com/2077-0383/11/6/1618atrial fibrillationanti-coagulationthrombosis |
| spellingShingle | Nobuyuki Fukuda Teruhiko Imamura Shuhei Tanaka Naoya Kataoka Ryuichi Ushijima Hiroshi Ueno Koichiro Kinugawa Comparison in Short-Term Safety and Efficacy between New-Generation WATCHMAN FLX and Conventional WATCHMAN 2.5 for Percutaneous Left Atrial Appendage Closure Journal of Clinical Medicine atrial fibrillation anti-coagulation thrombosis |
| title | Comparison in Short-Term Safety and Efficacy between New-Generation WATCHMAN FLX and Conventional WATCHMAN 2.5 for Percutaneous Left Atrial Appendage Closure |
| title_full | Comparison in Short-Term Safety and Efficacy between New-Generation WATCHMAN FLX and Conventional WATCHMAN 2.5 for Percutaneous Left Atrial Appendage Closure |
| title_fullStr | Comparison in Short-Term Safety and Efficacy between New-Generation WATCHMAN FLX and Conventional WATCHMAN 2.5 for Percutaneous Left Atrial Appendage Closure |
| title_full_unstemmed | Comparison in Short-Term Safety and Efficacy between New-Generation WATCHMAN FLX and Conventional WATCHMAN 2.5 for Percutaneous Left Atrial Appendage Closure |
| title_short | Comparison in Short-Term Safety and Efficacy between New-Generation WATCHMAN FLX and Conventional WATCHMAN 2.5 for Percutaneous Left Atrial Appendage Closure |
| title_sort | comparison in short term safety and efficacy between new generation watchman flx and conventional watchman 2 5 for percutaneous left atrial appendage closure |
| topic | atrial fibrillation anti-coagulation thrombosis |
| url | https://www.mdpi.com/2077-0383/11/6/1618 |
| work_keys_str_mv | AT nobuyukifukuda comparisoninshorttermsafetyandefficacybetweennewgenerationwatchmanflxandconventionalwatchman25forpercutaneousleftatrialappendageclosure AT teruhikoimamura comparisoninshorttermsafetyandefficacybetweennewgenerationwatchmanflxandconventionalwatchman25forpercutaneousleftatrialappendageclosure AT shuheitanaka comparisoninshorttermsafetyandefficacybetweennewgenerationwatchmanflxandconventionalwatchman25forpercutaneousleftatrialappendageclosure AT naoyakataoka comparisoninshorttermsafetyandefficacybetweennewgenerationwatchmanflxandconventionalwatchman25forpercutaneousleftatrialappendageclosure AT ryuichiushijima comparisoninshorttermsafetyandefficacybetweennewgenerationwatchmanflxandconventionalwatchman25forpercutaneousleftatrialappendageclosure AT hiroshiueno comparisoninshorttermsafetyandefficacybetweennewgenerationwatchmanflxandconventionalwatchman25forpercutaneousleftatrialappendageclosure AT koichirokinugawa comparisoninshorttermsafetyandefficacybetweennewgenerationwatchmanflxandconventionalwatchman25forpercutaneousleftatrialappendageclosure |